Menopause Clinical Trial
Official title:
Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar RF and PEMF Technologies for the Treatment of Symptoms Associated With Vulvovaginal Atrophy
NCT number | NCT04607798 |
Other study ID # | CS0416K |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 3, 2017 |
Est. completion date | May 31, 2020 |
Verified date | October 2020 |
Source | Venus Concept |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study evaluates the use of multi-polar radiofrequency (RF) and pulsed electro-magnetic fields (PEMF) energies for the treatment of symptoms related to genitourinary syndrome of menopause (GSM)/vulvovaginal atrophy (VVA). All subjects will receive a total of three internal treatments at four week intervals. Subjects will be followed up at one and four months after treatment is complete.
Status | Completed |
Enrollment | 40 |
Est. completion date | May 31, 2020 |
Est. primary completion date | May 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Healthy female subjects, =19 years of age presenting with symptoms associated with GSM/VVA. 2. Requesting treatment for vulvovaginal tissue for improvement of symptoms associated with GSM/VVA, with a score of ?26.55 on the FSFI. 3. Sexual activity (vaginal intercourse minimum twice per month) in a monogamous relationship. 4. At least one full-term pregnancy (>36 weeks gestation) with vaginal delivery completed at least one year before study enrollment. Exclusion Criteria: 1. Pregnant or intending to become pregnant during the course of study. 2. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator. 3. Having a permanent implant in the treated area (e.g. intrauterine device) 4. Prior use of collagen, fat injections and/or other methods of skin augmentation (enhancement with injected or implanted material) in the treated area within 4-6 weeks of the initial treatment or during the course of the study. 5. Use of retinoids such as oral Isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study. 6. Any other surgery in treated area within 12 months of initial treatment or during the course of the study. 7. Open laceration, abrasion, bleeding, infection or inflammation of any sort on or in the area to be treated. 8. Active sexual transmitted disease (STD) (e.g. genital Herpes Simplex, condylomata) or vaginosis. 9. Chronic vulvar pain or vulvar dystrophy. 10. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications, including corticosteroids, 6 months prior to and during the course of the study. 11. Having any form of active cancer at the time of enrollment and during the course of the study. 12. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the treatment, or healing process. 13. Participation in a study of another device or drug within 1 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria. 14. Mentally incompetent or evidence of active substance or alcohol abuse. 15. Having any stage 3-4 cystocele, rectocele, enterocele paravaginal defect or major pelvic organ prolapse beyond the hymenal ring. 16. Unstable dosages of medications such as antihypertensives or psychotropics that are known to affect sexuality. 17. Skin piercing in the treatment area. 18. Tattoos in the treatment area. 19. Prior skin treatment with laser in the treated area within 6 months of the initial treatment or during the course of treatment. 20. Prior ablative resurfacing procedure in the treated area with laser or other devices within 12 months of the initial treatment or during the course of treatment. 21. History of keloid formation or poor wound healing in a previously-injured skin area. 22. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity). 23. Menstruation less than 7 days prior to treatment. |
Country | Name | City | State |
---|---|---|---|
Ukraine | Cogerent Laser Clinics Group | Kyiv |
Lead Sponsor | Collaborator |
---|---|
Venus Concept |
Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vaginal Health Index | Clinician assessed improvement in five vaginal parameters; (1) vaginal fluid volume, (2) moisture, (3) vaginal epithelial integrity, (4) elasticity and (5) vaginal pH.
Assessed by the clinician at each visit with baseline comparison made at the one-month and four-month post-treatment assessments. |
Six months | |
Primary | pH | Clinician assessed improvement (reduction) in vaginal pH with baseline comparison made at the one-month and four-month post-treatment assessments. | Six months | |
Secondary | Female Sexual Function Index (FSFI) | Sexual dysfunction criteria (FSFI score =26.55) improvement as defined as increased FSFI > 26.55 with treatment; baseline comparison made at the one-month and four-month post-treatment assessments. | Six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04553029 -
A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
|
||
Completed |
NCT03672513 -
Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause
|
N/A | |
Terminated |
NCT03642119 -
Validation of an Objective Instrument to Measure Hot Flashes During Menopause
|
||
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04210583 -
RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Completed |
NCT05617287 -
An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause
|
N/A | |
Recruiting |
NCT05180266 -
Therapeutic Touch and Music in The Menopausal Period
|
N/A | |
Recruiting |
NCT04043520 -
Bioenergetic Effects of Aging and Menopause (BEAM)
|
Phase 4 | |
Completed |
NCT03663075 -
Effect of Group Education and Individual Counselling on Mental Health and Quality of Life in 45-60 Year Old Women
|
N/A | |
Completed |
NCT03363997 -
Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days
|
Phase 1 | |
Not yet recruiting |
NCT04728126 -
Menopausal Symptoms and Burnout: Comparison of Occupational Health Issue Among Health Professionals in UMC Hospitals
|
||
Not yet recruiting |
NCT04724135 -
Assessment of Menopause Related Quality of Life Among Health Professionals in University Hospitals of UMC in Nur-Sultan
|
||
Completed |
NCT02274571 -
Raising Insulin Sensitivity in Post Menopause
|
Early Phase 1 | |
Completed |
NCT02253173 -
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT02430987 -
Low Sexual Desire and Metabolic Syndrome
|
N/A | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A | |
Recruiting |
NCT01488903 -
A Cohort Research of Genetic Susceptibility for Common Obesity in Women
|
N/A | |
Terminated |
NCT01633814 -
Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women
|
N/A | |
Completed |
NCT00599456 -
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
|
N/A |